ATNX

Oraxol

Metastatic Breast Cancer

NDA Filing

Exp Date

H2 2020

Amp Volatility Score

24%

Catalyst Info & Data Links

TITLE: Oraxol for Metastatic Breast Cancer - NDA Filing 

  • ClinicalTrial.gov NCT02594371: Ph3 Study To Determine Safety, Tolerability & Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer


WHAT IS THE CATALYST EVENT?


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • H2 2020 


PRIOR DATA


PRESS RELEASES

COMPETITORS

MARKET

  • ~154,794 women living with MBC (in the United States) (source)


MECHANISM OF ACTION/ RATIONALE

  • A combination formulation composed of a capsule containing the taxane compound paclitaxel and a tablet containing the multidrug resistance (MDR) efflux pump P-glycoprotein (P-gp) inhibitor HM30181A, with potential antineoplastic activity. Upon oral administration of oraxol, the HM30181A moiety binds to and inhibits P-gp, which prevents P-gp-mediated efflux of paclitaxel, therefore enhancing its oral bioavailability. 

  • In turn, paclitaxel binds to and stabilizes microtubules, preventing their depolymerization, which results in the inhibition of cellular motility, mitosis, and replication. Altogether, this may result in greater intracellular concentration of paclitaxel, and enhanced cytotoxicity against tumor cells, when compared to the administration of paclitaxel alone. 

  • P-gp, encoded by the MDR-1 gene, is a member of the ATP-binding cassette (ABC) superfamily of transmembrane transporters; it prevents the intestinal uptake and intracellular accumulation of various cytotoxic agents (source).

Updated by HC

ATNX, oraxol, metastatic breast cancer, MBC, NDA

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

Will ATNX stock price pop if O...

ATNX's oraxol has shown some pretty good data in metastatic breast cancer. And oral paclitaxel vs. IV paclitaxel seems to have some patient convenience advantage. However, the stock has not responded ...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon